.4

PRESENTED BY: Phase 1 Trial R esults for IMA203CD8, a PRAME - Targeted T - cell Receptor (TCR) T - cell Therapy, in Ovarian C ancer Antonia Busse 1 , Winfried Alsdorf 2 , Oladapo O. Yeku 3 , Sarah E. Taylor 4 , Dejka M. Araujo 5 , Dirk Jaeger 6 , Katrin Wetzko 7 , Amir A. Jazaeri 8 , Samer Ali Srour 8 , Martin Wermke 9 , Alexander Mustea 10 , Friedrich Vollmer 11 , Norbert Hilf 11 , Nataliia Chorna 11 , Cedrik Michael Britten 11 , Tobias Albert Wilhelm Holderried 12 1 Charite Medical University Hospital, Berlin, Germany; 2 Department of Hematology and Oncology University Hospital Hamburg Eppendorf, Hamburg, Germany; 3 Massachusetts General Hospital, Harvard Medical School, Boston, MA; 4 Department of Obstetrics, Gynecology and Reproductive Services, University of Pittsburgh Medical Center, Pittsburgh, PA; 5 MD Anderson Cancer Center, Houston, TX; 6 Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany; 7 University Hospital Dresden, Dresden, Germany; 8 The University of Texas MD Anderson Cancer Center, Houston, TX; 9 TU Dresden University of Technology, NCT/UCC Early Clinical Trial Unit, Dresden, Germany; 10 Department of Gynecology and Gynecological Oncology, Bonn University Hospital, Bonn, Germany; 11 Immatics Biotechnologies GmbH, Tübingen, Germany; 12 University of Bonn, University Hospital Bonn, Medical Clinic and Polyclinic III Internal Medicine with a focus on Oncology, Hematology, and Rheumatology, Bonn, Germany Prof. Dr. med. Antonia Busse, A bstract #5509

PRESENTED BY: Key T akeaways • TCR - based therapies enable immune recognition of intracellular tumor antigens presented by cell - surface HLA, expanding the therapeutic landscape beyond targets accessible to conventional immunotherapies • IMA203CD8 is a one - time autologous TCR T - cell therapy targeting the cancer - associated antigen PRAME, which is broadly expressed in gynecologic cancers and represents a novel target for immunotherapies in this patient population • IMA203CD8 demonstrates a predictable and manageable tolerability profile and encouraging dose - dependent activity in patients with advanced gynecologic cancers • These findings support further development of IMA203CD8 to define its therapeutic potential in patients with gynecologic and other PRAME - positive cancers HLA: human leukocyte antigen; PRAME: preferentially expressed antigen in melanoma; TCR: T - cell receptor Prof. Dr. med. Antonia Busse, A bstract #5509 Data cutoff Mar 30, 2026

PRESENTED BY: IMA203CD8 is a Systemic TCR T - cell Therapy Designed to Target the Intracellular Tumor Antigen PRAME IMA203CD8 is an investigational therapy and its use has not been proven to be safe or effective. It has not been approved by the FDA or any other regulatory agency outside of the US. a Data on file: PRAME target prevalence is based on a proprietary mass spec - guided expression threshold applied to RNAseq data (approximate values; values between 95 - 100% shown as 95%). b Includes the following subtypes: clear cell carcinoma, endometrioid carcinoma, serous cystadenocarcinoma; HLA, human leukocyte antigen; NSCLC, non - small cell lung cancer; PRAME, preferentially expressed antigen in melanoma; TCR, T - cel l receptor. PRAME is expressed in >50 cancers % PRAME+ patients a Indication 95% Cutaneous Melanoma 95% Uterine Carcinoma 95% Uterine Carcinosarcoma 95% Synovial Sarcoma 90% Uveal Melanoma 90% Mucosal Melanoma 85% Ovarian Carcinoma Subtypes b 70% Squamous Cell NSCLC 65% Triple - negative Breast Carcinoma 45% Small Cell Lung Cancer 45% Esophageal Carcinoma Subtype 40% Kidney Carcinoma Subtype 35% Cholangiocarcinoma 30% HER2 - Enriched Breast Carcinoma 25% Adenocarcinoma NSCLC 25% Head & Neck Squamous Cell Carcinoma 20% Hepatocellular Carcinoma 20% Bladder Carcinoma Mechanism of action Prof. Dr. med. Antonia Busse, A bstract #5509

PRESENTED BY: Phase 1 Multicenter Trial of IMA203CD8 in PRAME+ Solid Tumors IMA203 - 101: NCT03686124; Based on initial safety data observed with anzu - cel (IMA203), IMA203CD8 dose escalation was initiated at DL3. Total TCR T cells calculated from defined number of TCR T cells /m 2 BSA per dose level x 1.8 m 2 BSA; a Dose level ≥ DL4c is evaluated “ IL - 2 , starting without IL - 2. If tolerable, add IL - 2 at the same dose or escalate to next dose without IL - 2; outpt IL - 2 admin . at investigator’s discretion. BID, twice daily; BSA, body surface area; DL, dose level; ECOG PS, Eastern Cooperative Oncology Group Performance Status; FU, follow - up; IL, interleukin; IU, international unit; PRAME, preferenti ally expressed antigen in melanoma; QD, daily; SOC, standard of care; SUBQ, subcutaneous; TCR, T - cell receptor. PRAME Testing Biopsy or archived tissue No longer required for indications with high PRAME prevalence, including ovarian and uterine cancer IMA203CD8 Manufacturing (~2 weeks) Lymphodepletion Fludarabine 30mg/m 2 Cyclophosphamide 500mg/m 2 Days - 6 to - 3 ц Low Dose IL - 2 a 1M IU SUBQ QD x 3d, then 1M IU SUBQ BID x 5d Leukapheresis HLA - A*02:01 Testing (blood) Patient Journey SCREENING / MANUFACTURING TREATMENT / OBSERVATION FU IMA203CD8 one - time infusion Enrichment at relevant DLs: ~1.4 – 10 billion total TCR T cells DL3 (n=1) ~0.36 - 0.86 x 10 9 total TCR T cells DL4a (n=6) ~0.87 - 1.44 x 10 9 total TCR T cells DL4c (n=2) ~1.45 - 2.16 x 10 9 total TCR T cells DL5 (n=5) ~2.17 - 3.6 x 10 9 total TCR T cells DL6 (n=8) ~3.6 - 7.2 x 10 9 total TCR T cells DL7 (n=5) ~7.2 - 10 x 10 9 total TCR T cells Dose Escalation Scheme Key Objectives Primary: • Tolerability • Determination of RP2D Secondary: • Efficacy • Pharmacokinetics Key Eligibility Criteria • Advanced or metastatic solid tumors • Age ≥ 18 years • ECOG PS 0 - 1 • HLA - A*02:01 positive • PRAME positive • No available SOC treatment options • Measurable disease (RECIST 1.1) • Adequate organ function Data cutoff Mar 30, 2026 Prof. Dr. med. Antonia Busse, A bstract #5509

PRESENTED BY: Patient Disposition a All patients who started lymphodepletion; b All patients who received IMA203CD8 infusion and had at least one post - baseline scan, progressive disease or death; DL, dose le vel; NSCLC, non - small cell lung cancer. Safety Population a N=90 Melanoma n=46 Synovial Sarcoma n=12 Gynecologic Indications n=27 Efficacy - evaluable Population b n=26 < DL4c n=7 Ovarian Carcinoma n=6 Uterine Cancer n=1 ≥ DL4c n=19 Ovarian Carcinoma n=17 Uterine Cancer n=2 Other n=5 Araujo et al, ASCO 2026 Busse et al, ESMO - IO 2025 Busse et al, ESMO - IO 2025 Cutaneous melanoma n=24 Uveal melanoma n=16 Mucosal melanoma n=3 Melanoma of unknown primary n=2 Acral melanoma n=1 Triple - negative breast cancer n=3 Lung adenocarcinoma n=1 NSCLC n=1 n=1 pending first post - baseline scan n=1 at DL3 n=6 at DL4a Data cutoff Mar 30, 2026 Prof. Dr. med. Antonia Busse, A bstract #5509

PRESENTED BY: Patients Were Heavily Pretreated with Limited Treatment Options n =27, includes all patients who started lymphodepletion; a Includes 1 patient with endometrial carcinoma; ADC, antibody - drug - conjugate; ECOG PS, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase; na , not applicable; PARPi , PARP inhibitor; SLD, sum of longest diameter(s); TCR, T - cell receptor; ULN, upper limit of normal. Uterine Cancer a Ovarian Carcinoma n=3 n=24 52 (49, 55) 60 (35, 75) Age, median (range) 0 10 (42) ECOG PS 1 , n (%) 2 (67) 8 (33) LDH ≥1 x ULN, n (%) 8.1 (1.1, 12.4) 6.2 (1.5, 21.6) Tumor burden Target lesion SLD [cm], median (range) 4 (1, 4) 2 (1, 5) Number of target tumor lesions, median (range) 1 (33) 21 (88) Cancer subtype, high - grade serous , n (%) 2 (67) 10 (42) Liver metastasis, n (%) 3 (100) 17 (71) Peritoneal disease , n (%) na 19 (79) Platinum - resistant, n (%) Baseline Characteristics Uterine Cancer a Ovarian Carcinoma n=3 n=24 1 (33) 3 (100) 4 (17) 24 (100) Prior treatment, n (%) Radiation Systemic treatment 2 (1, 3) 1 (33) 4 (1, 7) 22 (92) Prior lines of systemic treatment Median, (range) ≥3, n (%) na 3 (100) 1 (1, 1) 3 (100) 1 (1, 1) - - 3 (100) 1 (0, 2) 24 (100) 3 (1, 5) 24 (100) 3 (1, 4) 18 (75) 17 (71) 2 (8) Lines post - platinum resistance, med (range) Chemotherapy, n (%) Lines of chemotherapy, median (range) Platinum - based regimen, n (%) Lines of platinum - based regimen, median (range) Targeted therapies, n (%) Bevacizumab PARPi Checkpoint inhibitors Treatment Experience n=3 n=24 Dose 3.2 (1.3, 10.1) 3.3 (0.5, 12.5) Total infused dose TCR T cells [x10 9 ], median (range) Data cutoff Mar 30, 2026 Prof. Dr. med. Antonia Busse, A bstract #5509

PRESENTED BY: Safety in Patients with Gynecologic Indications (n=27 a ) Tolerability across all indications: Busse et al ESMO - IO, 2025. a Includes all patients who started lymphodepletion; b One grade 5 event at DL4a (~1.4 billion total TCR T cells) was deemed to be unlikely related to IMA203CD8 by investigator. Pa ti ent died from sepsis in the setting of IEC - HS. This event led to further modifications of eligibility criteria to exclude patients at higher risk for infectious complications or severe immune - r elated toxicities, together with IL - 2 de - intensification; no further treatment - emergent fatal events were observed with escalati ng doses up to ~10 billion total TCR T cells. AE, adverse event; CRS, cytokine release syndrome; d, day; DL, dose level; DLT, do se - limiting toxicity; HLH, hemophagocytic lymphohistiocytosis; ICANS, immune effector cell - associated neurotoxicity syndrome; TCR, T - cell receptor; TEAE, treatment - emergent adverse event. Overall manageable tolerability profile • Most frequent TEAEs were anticipated cytopenias associated with lymphodepletion • Expected and manageable CRS, mostly grade 1 - 2, consistent with mechanism of action • 2 DLTs: – DL5: Grade 3 ICANS – DL7: G rade 4 skin infection • MTD not reached • No IMA203CD8 - related grade 5 events b Adverse events of special interest TEAEs in ≥25% of patients Any Time Grade ≥ 3 Any grade Preferred term, n (%) 0 22 (81) Nausea 20 (74) 20 (74) Neutropenia 17 (63) 18 (67) Anaemia 3 (11) 16 (59) Rash 11 (41) 16 (59) Thrombocytopenia 2 (7) 13 (48) Abdominal pain 0 12 (44) Vomiting 0 11 (41) Fatigue 1 (4) 10 (37) Hypokalaemia 0 9 (33) Constipation 9 (33) 9 (33) Lymphopenia 2 (7) 8 (30) Hypophosphataemia 0 8 (30) Pyrexia 1 (4) 7 (26) Hypomagnesaemia 0 7 (26) Hyponatraemia Any Time 26 (96) CRS, any grade, n (%) 12 (44) Grade 1 12 (44) Grade 2 2 (7) Grade 3 2 (7) HLH, any grade, n (%) 0 Grade 1 1 (4) Grade 2 0 Grade 3 1 (4) Grade 4 2 (7) ICANS, any grade, n (%) 1 (4) Grade 1 0 Grade 2 1 (4) Grade 3 Data cutoff Mar 30, 2026 Prof. Dr. med. Antonia Busse, A bstract #5509

PRESENTED BY: BOR in Patients with Gynecologic Indications at All DL (n=26 a ) Evaluable patients ≥DL4c 63% (12/19) ORR b 50% (9/18) cORR c 68% (13/19) DCR (at week 6)                                           ,QGLFDWLRQ           7DUJHW/HVLRQVIURP%DVHOLQH  5(&,67     %HVW  &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI %DVHOLQH :DWHUIDOO3ORW 6RUWHGE\'/*(  &)/  1ILUVW  WKHQ< 3RSXODWLRQ  $OOSDWLHQWV 'DWDFXW  RII       * * + ≥DL4c <DL4c Baseline PD Best overall response (RECIST 1.1) SD PR cPR CR cCR Ongoing a Two patients with ovarian cancer at DL4a and DL5 deceased prior to first post - BL scan non - evaluable for assessment of tumor redu ction, not depicted in plot but assessed for ORR calculation; b ORR: according to RECIST 1.1 at any post - BL scan, PD or death at any prior timepoint; c Confirmed ORR for patients with ≥2 post - BL scans per RECIST 1.1, PD or death at any prior timepoint, those with ongoing unconfi rmed PR/CR were excluded. * For those patients who achieved a (c)CR with <100% changes from baseline, target lesions were lymph nodes that resolved to <10 mm per RECIST 1.1; + Patient had a PR prior to CR. BL, baseline; BOR, best overall response; (c)CR, (confirmed) complete response; DCR, disease co nt rol rate; DL, dose level; (c)ORR, (confirmed) objective response rate; PD, progressive disease; (c)PR, (confirmed) partial response; SD, stable disease. Data cutoff Mar 30, 2026 Prof. Dr. med. Antonia Busse, A bstract #5509 Tumor reduction: 78% (14/18)

PRESENTED BY: PD Best overall response (RECIST 1.1) SD PR cPR CR cCR Ongoing Ovarian Cancer Indication Uterine Cancer # 'DWDFXW  RII       3RSXODWLRQ  *\Q2QF%XQGOH  ,0$  &'  LQ'/  FRUKLJKHU 6SLGHU3ORW 8WHULQH&DQFHU 2YDULDQ&DQFHU ,QGLFDWLRQ 3' 6' 35 F35 &5 F&5 %HVWRYHUDOOUHVSRQVH  5(&,67          0RQWKVSRVW7FHOOLQIXVLRQ              7DUJHW/HVLRQVIURP%DVHOLQH >@ &KDQJHLQ6XPRI/RQJHVW'LDPHWHURI 3' %DVHOLQH 35 2QJRLQJ Months Post T - cell Infusion # Changes in Tumor Size Over Time in Patients with Gynecologic Indications at ≥DL4c (n=19 a ) a One patient with ovarian cancer at DL5 deceased prior to first post - BL scan non - evaluable for assessment of tumor reduction, not de picted in plot but assessed for ORR calculation. For those patients who achieved a (c)CR with <100% changes from baseline, target lesions were lymph nodes that resolved to <10 mm per RECIST 1.1; # Ongoing confirmed PR (RECIST 1.1) as of l ast scan at month 7.5, suspected clinical progression by clinical site at month 6 in discrepancy to RECIST response due to tumor marker increase; patient off study at month 8 and receiving further anti - tumor treatment. BOR, best overall response; (c)C R, (confirmed) complete response; DCR, disease control rate; (c)ORR, (confirmed) objective response rate; PD, progressive disease; (c)PR, (confirmed) partial response; SD, stable disease. Data cutoff Mar 30, 2026 Prof. Dr. med. Antonia Busse, A bstract #5509 • 89% (8/9) of confirmed responses ongoing • longest ongoing response at 12 months post infusion (metabolic complete response)

PRESENTED BY: Conclusions • TCR - based therapies enable immune recognition of intracellular tumor antigens presented by cell - surface HLA, expanding the therapeutic landscape beyond targets accessible to conventional immunotherapies • IMA203CD8 is a one - time autologous TCR T - cell therapy targeting the cancer - associated antigen PRAME, which is broadly expressed in gynecologic cancers and represents a novel target for immunotherapies in this patient population • IMA203CD8 demonstrates a predictable and manageable tolerability profile and encouraging dose - dependent activity in patients with advanced gynecologic cancers • These findings support further development of IMA203CD8 to define its therapeutic potential in patients with gynecologic and other PRAME - positive cancers HLA, human leukocyte antigen; PRAME, preferentially expressed antigen in melanoma; TCR, T - cell receptor. Prof. Dr. med. Antonia Busse, A bstract #5509 Data cutoff Mar 30, 2026

PRESENTED BY: University Hospital Dresden University Hospital Bonn University Hospital Hamburg Charité Berlin University Hospital Heidelberg TUM University Hospital Munich IMA203 - 101 Phase 1 Trial (patients with gynecologic indications) Sponsor: Immatics Massachusetts General Hospital University of Pittsburgh Medical Center UT MD Anderson United States Thank You – Trial Participants & Caregivers Germany Prof. Dr. med. Antonia Busse, A bstract #5509

PRESENTED BY: Appendix Prof. Dr. med. Antonia Busse, A bstract #5509

PRESENTED BY: 0 10 20 30 1×10 1 1×10 2 1×10 3 1×10 4 1×10 5 1×10 6 1×10 7 40 60 80 1002004006008001000 Days post-infusion V e c t o r c o p i e s / µ g D N A Long - Term IMA203CD8 T - cell Persistence in Peripheral Blood Prof. Dr. med. Antonia Busse Sustained persistence of IMA203CD8 T cells beyond 1 - year post - infusion represent an important prerequisite for durable clinical benefit Data cutoff Mar 30, 2026

PRESENTED BY: Patients with Gynecologic Cancers Treated with IMA203CD8 at Doses ≥DL4c in Phase 1 (n=19) BOR, best overall response; DL, dose level; (c)CR, (confirmed) complete response; cPR , confirmed partial response; OC, ovarian cancer; PARPi , PARP inhibitor; PFS, progression free survival. Reason for Progression Comment BOR (Max % change of target lesions) BOR DL Total infused dose TCR - T cells 1 [x10 9 ] Prior treatments No of prior systemic treatment lines Indication Ongoing response at 5.3 months PFS, deepened from initial PR - 100 CR 5 3.15E+09 Pembrolizumab + Chemotherapy (carboplatin, paclitaxel) 1 Uterine Cancer Target lesion progression, new lesions Response until 2.8 months PFS - 100 CR 5 3.08E+09 Bevacizumab + chemotherapy (carboplatin, paclitaxel) PARPi Chemotherapy (caelyx, carboplatin) PARPi 4 OC, Fall tupe, perit. Suspected clinical progression by clinical site in discrepancy to RECIST response due to tumor marker increase Response until 7.4 months PFS - 74.4 cPR 5 2.30E+09 Chemotherapy (carboplatin, paclitaxel) Bevacizumab + chemotherapy (carboplatin, paclitaxel) PARPi + chemotherapy (caelyx, carboplatin) Chemotherapy (carboplatin, cisplatin, gemcitabine) Chemotherapy (paclitaxel) 5 OC, Fall tupe, perit. Ongoing response at 12.2 months PFS; metabolic complete response - 66.9 cPR 6 7.07E+09 Chemotherapy (carboplatin, paclitaxel) Bevacizumab + chemotherapy (carboplatin, paclitaxel) PARPi + chemotherapy (carboplatin, gemcitabine) Chemotherapy (carboplatin, doxorubicin) 4 OC, Fall tupe, perit. Ongoing response at 6.2 months PFS - 60.8 cCR 6 6.22E+09 Bevacizumab + chemotherapy (carboplatin, paclitaxel) Chemotherapy (carboplatin, doxorubicin) Chemotherapy (carboplatin, gemcitabine) Chemotherapy (paclitaxel) Chemotherapy (docetaxel) 5 OC, Fall tupe , perit . Ongoing response at 5.3 months PFS - 46.7 cCR 4c 1.43E+09 Chemotherapy (carboplatin, paclitaxel) 1 OC, Fall tupe, perit. Ongoing response at 4.6 months PFS - 43.6 cPR 6 6.59E+09 Chemotherapy (carboplatin, taxol ) PARPi Chemotherapy (carboplatin, caelyx ) PARPi PARPi Chemotherapy (carboplatin, gemcitabine) 6 OC, Fall tupe , perit . Ongoing response at 3.0 months PFS - 40.2 cPR 6 4.16E+09 Bevacizumab + PARPi + chemotherapy (paclitaxel, docetaxel, carboplatin) Chemotherapy (doxorubicin, carboplatin, gemcitabine) Chemotherapy (carboplatin, cyclophosphamide) 3 OC, Fall tupe, perit. Ongoing response at 5.3 months PFS - 38.2 cPR 7 12.5E+9 Chemotherapy (carboplatin, taxol) Chemotherapy (carboplatin, gemcitabine) Chemotherapy (mitomycin) Chemotherapy (cisplatin, paclitaxel) 4 OC, Fall tupe, perit. Prof. Dr. med. Antonia Busse Data cutoff Mar 30, 2026

PRESENTED BY: Patients with Gynecologic Cancers Treated with IMA203CD8 at Doses ≥DL4c in Phase 1 (n=19) BOR, best overall response; DL, dose level; (c)PR, (confirmed) partial response; SD, stable disease; PD, progressive disease; PARPi , PARP inhibitor; OC, ovarian cancer; PFS, progression free survival. Reason for Progression Comment BOR (Max % change of target lesions) BOR DL Total infused dose TCR - T cells 1 [x10 9 ] Prior treatments No of prior systemic treatment lines Indication Ongoing response at 2.5 months PFS - 60.9 cPR 7 7.48E+09 Chemotherapy (carboplatin, paclitaxel) 1 OC, Fall tupe, perit. Target and Non - target lesion progression Unconfirmed response until 3.0 months PFS - 40 PR 7 11.0E+9 Chemotherapy (carboplatin, paclitaxel) Chemotherapy (carboplatin, gemcitabine) PARPi + ICI + exp. Therapy Chemotherapy (paclitaxel) 4 OC, Fall tupe, perit. Ongoing unconfirmed response at 4.5 months PFS, deepened from initial SD - 34.7 PR 7 10.1E+9 Chemotherapy (carboplatin, paclitaxel) Exp. therapy (selinexor) TKI + ICI 3 Uterine Cancer New lesions Disease stabilization until 3.0 months PFS - 8.1 SD 4c 2.26E+09 Chemotherapy (carboplatin, taxol) Chemotherapy (carboplatin, paclitaxel) Bevacizumab Exp. therapy (AVB - 001) Bevacizumab + Chemotherapy (carboplatin, gemcitabine, gemzar) 5 OC, Fall tupe, perit. Target and non - target progression, new lesions Progressive disease at 1.5 months PFS - 40 PD 6 3.55E+09 PARPi + chemotherapy (carboplatin, paclitaxel) Bevacizumab PARPi + chemotherapy ( caelyx , carboplatin) Chemotherapy (topotecan) 4 OC, Fall tupe , perit . New lesions Progressive disease at 1.4 months PFS 2.4 PD 6 5.38E+09 Bevacizumab + PARPi + chemotherapy (carboplatin, paclitaxel) Chemotherapy (carboplatin, doxorubicin) Chemotherapy (paclitaxel) 3 OC, Fall tupe , perit . Non - target progression Progressive disease at 1.4 months PFS 2.6 PD 6 6.46E+09 Chemotherapy (carboplatin, paclitaxel) Bevacizumab + PARPi + chemotherapy (carboplatin, doxorubicin) Mirvetuximab Chemotherapy (topotecan) 4 OC, Fall tupe , perit . Target and non - target progression, new lesions Progressive disease at 1.4 months PFS 14.2 PD 5 3.02E+09 PARPi + chemotherapy (carboplatin, taxol) Bevacizumab + chemotherapy (carboplatin, doxorubicin) ADC (PRO1184) 3 OC, Fall tupe, perit. Target lesion progression, new lesions Progressive disease at 1.3 months PFS 21.7 PD 7 6.42E+09 Chemotherapy (carboplatin, paclitaxel) PARPi Chemotherapy (carboplatin, doxorubicin) 3 OC, Fall tupe, perit. Death Progressive disease at 1.1 months n/a PD 5 3.04E+09 Bevacizumab + chemotherapy (carboplatin, paclitaxel) Chemotherapy ( caelyx , carboplatin) Chemotherapy (carboplatin, gemcitabine) 3 OC, Fall tupe , perit . Prof. Dr. med. Antonia Busse Data cutoff Mar 30, 2026